

DT04 Rec'd PCT/PTO 0 4 OCT 2004

Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	SERIAL NO. 10/510319
	APPLICANT Patrice HILDGEN et al	
	FILING DATE	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5 6 8 3 7 2 3	1997	G. SPENLEHAUER et al			
		6 0 0 7 8 4 5	1999	A.J. DOMB et al			
		6 1 3 9 8 7 0	2000	T. VERRECHIA			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
WO	01	1 2 7 1 8	2001	International publication				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

1)	« Vecteurs polymériques injectables pour l'administration des anticancéreux », PANOYAN, Avedis et al, XP-02257860 68 ^e Congrès de l'Acfas, Session : S-154 Pharmacologie et toxicologie
2)	« Long-circulating nanoparticles using biodegradable ABA triblock copolymers containing poly(L-lactic acid) A-blocks attached to central poly(oxyethylene) B-blocks, Yuichiro NAKARA et al, Pharmaceuticals research Center and Research and Development Center, Kanebo Ltd., XP-000783648 accepted August 13, 1997, pp. 479-481
3)	"Clonazepam release from core-shell type nanoparticles of poly(ϵ -caprolactone)/poly(ethylene glycol)/poly(ϵ -caprolactone) triblock copolymers", Jae-Gon RYU et al, College of Pharmacy, Chosun University, South Korea, Department of Polymer Science and Eng., South Korea, International Journal of Pharmaceutics, 200 (2000) 231-242, XP-002257858 accepted 13 March 2000, pp. 231-242
EXAMINER	/Susan Berman/
DATE CONSIDERED	06/12/2008
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.B./